What is Nutcracker Therapeutics?
Nutcracker Therapeutics operates as a pioneering contract research, development, and manufacturing organization (CRDMO) with a specialized focus on RNA-based therapeutics for personalized medicine. The company has engineered a comprehensive end-to-end platform designed to overcome critical industry hurdles in RNA design, nanoparticle delivery, and precision manufacturing. By enhancing the speed, scalability, and safety of RNA therapeutic development, Nutcracker Therapeutics aims to accelerate the delivery of life-saving treatments for a spectrum of diseases, fostering collaborations to bring novel RNA therapies to patients.
How much funding has Nutcracker Therapeutics raised?
Nutcracker Therapeutics has raised a total of $227M across 2 funding rounds:
Series B
$60M
Series C
$167M
Series B (2020): $60M with participation from ARCH Venture Partners
Series C (2022): $167M led by ARCH Venture Partners
Key Investors in Nutcracker Therapeutics
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
What's next for Nutcracker Therapeutics?
The recent major strategic investment positions Nutcracker Therapeutics for accelerated growth and expansion of its RNA therapeutic development capabilities. This significant capital infusion, part of its $227M in total funding, will likely fuel advancements in its proprietary platform, enabling the company to scale its operations and potentially broaden its therapeutic pipeline. The company's focus on personalized medicine and its CRDMO model suggest a strategic direction towards forging key partnerships and collaborations to expedite the clinical translation of RNA-based innovations.
See full Nutcracker Therapeutics company page
